At Galapagos, we believe that transparency of clinical trial data promotes strong scientific research and advances science and medicine. We support the overall principles of greater clinical trial data transparency and make our scientific publications freely available via open access.
A clinical trial tests a potential drug, medical device, activity, or procedure in people. At Galapagos, we commit to register Galapagos-sponsored Phase 1, Phase 2, Phase 3, and Phase 4 clinical trials conducted in any geographical territory that started as of 1st of January 2021. We further commit to make a summary of the results of these Galapagos-sponsored Phase 2, Phase 3, and Phase 4 clinical trials publicly available within 6 months of completion for pediatric studies and 12 months for adult studies. The clinical trials and summary results will be registered on Clinicaltrials.gov and/or the EU Clinical Trials Register. We publish results of clinical trials as of Phase 2 in peer-reviewed scientific journals in a timely manner.
We release, either by submitting to regulatory authorities or by posting directly to clinical trial registries, actual clinical trial documents, such as protocols and study reports, as required by law and/or regulation.
We commit to ensure full compliance with all applicable laws and regulatory guidance and provide specific attention to the protection of personal data at a clinical trial participant level.